NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043. The patent covers compositions combining an anti-inflammatory drug and a Dicer activator for neuronal diseases, which the company says strengthens its intellectual property for long-term development and potential commercialization.
NeuroSense also completed a proof-of-concept Alzheimer's study (RoAD) with top-line results showing a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in Q1 2026.
Positive
- U.S. patent granted covering PrimeC use in Alzheimer's, protection through 2043
- Proof-of-concept study (RoAD) completed with favorable safety and tolerability
- Patent strengthens intellectual property position for potential commercialization
Negative
- Clinical efficacy and biomarker readouts are still pending, expected in Q1 2026
- No revenue, approval, or commercialization timeline disclosed
Details
News Market Reaction – NRSN
On Jan 21, the day this news came out, NRSN closed 5.19% below the previous close.
Data tracked by StockTitan Argus for the Jan 21 session.
Key Figures
- Patent protection
- Through 2043
- U.S. patent for PrimeC combination in Alzheimer’s disease
- RoAD study patients
- 8 patients
- Proof-of-concept Phase 2 Alzheimer’s RoAD study
- PARAGON sample size
- 300 participants
- Pivotal Phase 3 ALS trial design
- Alzheimer’s readout timing
- Q1 2026
- Clinical and biomarker outcomes from RoAD study
- Registered resale shares
- 333,334 ordinary shares
- Form F-3 shelf registration for selling shareholder
- Shares outstanding
- 29,550,970 shares
- Ordinary shares outstanding as of October 27, 2025
- Private placement price
- $1.50 per share
- September 2025 private placement
- Private placement proceeds
- $0.5 million gross
- September 2025 private placement
Historical Context
-
Alzheimer’s expert joined SAB supporting PrimeC programs and RoAD study.
-
Phase 2 Alzheimer’s study reported favorable safety and tolerability, no SAEs.
-
Resumed Canadian ALS regulatory activity toward pre‑NDS meeting and NDS plan.
-
FDA cleared pivotal Phase 3 PARAGON ALS trial under IND amendment.
-
Scheduled investor webinar to cover ALS, Alzheimer’s and regulatory updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biomarker medical
anti-inflammatory drug medical
dicer activator medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Patent protection extended through 2043
- Alzheimer's proof-of-concept study completed
- Clinical and Biomarker Outcomes Expected in Q1 2026
The granted patent provides protection for the use of PrimeC combination in Alzheimer's disease, strengthening NeuroSense's intellectual property estate and supporting the program's long-term development and potential commercialization, with protection extending through 2043.
"This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "It reflects both the breadth of the underlying biology and our strategy to build durable protection as we advance PrimeC combination clinically in Alzheimer's disease and other neurodegenerative conditions."
NeuroSense recently concluded its proof-of-concept Alzheimer's disease study (RoAD), with top-line results demonstrating a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in the first quarter of 2026.
About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the timing of the reporting of additional data from the study of PrimeC in Alzheimer's disease, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-granted-us-patent-for-treatment-of-alzheimers-disease-302666624.html
SOURCE NeuroSense
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.